SI1176964T1 - Uporaba et743 za zdravljenje raka - Google Patents

Uporaba et743 za zdravljenje raka

Info

Publication number: SI1176964T1
Authority: SI; Slovenia
Prior art keywords: treating cancer; cancer; treating
Prior art date: 1999-05-13

Application number

SI200030905T

Other languages

English (en)

Inventor

Angela Dept Of Clinical Bowman

Esteban Cvitkovic

George Daniel Dept Of Demetri

Cecilia Pharma Mar S A Guzman

Jose Pharma Mar S A Jimeno

Lazaro Luis Pharma Mar S Lopez

Jean Louis Service D On Misset

C Uni Of Glasgow Crc B Twelves

Hoff Daniel D Arizona Canc Von

Original Assignee

Pharma Mar Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-13

Filing date

2000-05-15

Publication date

2007-02-28

1999-05-13 Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en

1999-05-14 Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en

1999-08-05 Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en

1999-11-15 Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en

1999-11-16 Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en

2000-03-29 Priority claimed from GB0007637A external-priority patent/GB0007637D0/en

2000-05-15 Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa

2007-02-28 Publication of SI1176964T1 publication Critical patent/SI1176964T1/sl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Oncology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)

SI200030905T 1999-05-13 2000-05-15 Uporaba et743 za zdravljenje raka SI1176964T1 (sl)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
GBGB9911183.3A GB9911183D0 (en)	1999-05-13	1999-05-13	Treatment of cancers
GBGB9911346.6A GB9911346D0 (en)	1999-05-14	1999-05-14	Treatment of cancers
GBGB9918534.0A GB9918534D0 (en)	1999-08-05	1999-08-05	Treatment of cancers
GBGB9927005.0A GB9927005D0 (en)	1999-11-15	1999-11-15	Treatment of cancers
GBGB9927106.6A GB9927106D0 (en)	1999-11-16	1999-11-16	Cancer treatment
GB0007637A GB0007637D0 (en)	2000-03-29	2000-03-29	Antitumour compound
PCT/GB2000/001857 WO2000069441A1 (en)	1999-05-13	2000-05-15	Compositions and uses of et743 for treating cancer

Publications (1)

Publication Number	Publication Date
SI1176964T1 true SI1176964T1 (sl)	2007-02-28

Family

ID=27546594

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SI200031067T SI1716853T1 (sl)	1999-05-13	2000-05-15	Zdravljenje rakov äśloveĺ kega telesa z uporabo et743
SI200030905T SI1176964T1 (sl)	1999-05-13	2000-05-15	Uporaba et743 za zdravljenje raka
SI200030977T SI1702618T1 (sl)	1999-05-13	2000-05-15	Uporaba et743 v kombinirani terapiji z deksametazonom za zdravljenje raka

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SI200031067T SI1716853T1 (sl)	1999-05-13	2000-05-15	Zdravljenje rakov äśloveĺ kega telesa z uporabo et743

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200030977T SI1702618T1 (sl)	1999-05-13	2000-05-15	Uporaba et743 v kombinirani terapiji z deksametazonom za zdravljenje raka

Country Status (32)

Country	Link
US (1)	US8119638B2 (sl)
EP (3)	EP1702618B1 (sl)
JP (2)	JP2002544231A (sl)
KR (1)	KR20020019914A (sl)
CN (2)	CN1360503A (sl)
AR (1)	AR028476A1 (sl)
AT (3)	ATE375795T1 (sl)
AU (2)	AU777417B2 (sl)
BG (1)	BG65680B1 (sl)
BR (1)	BR0010531A (sl)
CA (1)	CA2373794C (sl)
CY (4)	CY1105818T1 (sl)
CZ (1)	CZ301482B6 (sl)
DE (4)	DE60030554T8 (sl)
DK (3)	DK1716853T3 (sl)
ES (2)	ES2294756T3 (sl)
FR (1)	FR08C0013I2 (sl)
HU (2)	HU229866B1 (sl)
IL (2)	IL146434A0 (sl)
LU (1)	LU91418I2 (sl)
MX (1)	MXPA01011562A (sl)
MY (1)	MY164077A (sl)
NL (1)	NL300337I2 (sl)
NO (2)	NO324564B1 (sl)
NZ (1)	NZ515423A (sl)
PL (1)	PL198185B1 (sl)
PT (3)	PT1176964E (sl)
SI (3)	SI1716853T1 (sl)
SK (1)	SK287580B6 (sl)
TR (1)	TR200103819T2 (sl)
UA (1)	UA74782C2 (sl)
WO (1)	WO2000069441A1 (sl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
CN100374162C (zh) *	2000-11-06	2008-03-12	法马马有限公司	海鞘素－743在制备用于治疗肿瘤的药剂中的应用
GB0117402D0 (en) *	2001-07-17	2001-09-05	Pharma Mar Sa	New antitumoral derivatives of et-743
CA2462502A1 (en) *	2001-10-19	2003-05-15	Pharma Mar, S.A.	Improved use of antitumoral compound in cancer therapy
GB0202544D0 (en)	2002-02-04	2002-03-20	Pharma Mar Sa	The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) *	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
PL1689404T3 (pl) *	2003-11-13	2009-02-27	Pharma Mar Sau	Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
EP1691809A1 (en) *	2003-11-14	2006-08-23	Pharma Mar, S.A.	Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) *	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
US20080293725A1 (en) *	2004-07-09	2008-11-27	Rafael Rosell Costa	Prognostic Molecular Markers
UA87877C2 (en) *	2004-10-26	2009-08-25	Фарма Мар С.А., Сосьедад Униперсональ	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (da) *	2004-10-29	2007-11-26	Pharma Mar Sa	Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) *	2005-10-31	2005-12-07	Pharma Mar Sa	Formulations
US20100009906A1 (en) *	2006-05-12	2010-01-14	Pharma Mar, S.A.	Anticancer Treatments
JP2011500046A (ja) *	2007-10-19	2011-01-06	ファルマ・マール・ソシエダード・アノニマ	Ｅｔ−７４３治療のための予後分子マーカー
BR112018015118A2 (pt) *	2016-02-04	2018-12-18	Jiangsu Hengrui Medicine Co., Ltd.	composição farmacêutica injetável inclusiva de trabectedina para uso externo gastrointestinal e método de fabricação da mesma
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام
WO2020239478A1 (en)	2019-05-28	2020-12-03	Pharma Mar, S.A.	Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) *	2019-09-27	2022-05-24	江苏恒瑞医药股份有限公司	一种海鞘素衍生物的制备方法
AU2021256746A1 (en)	2020-04-15	2022-11-03	Ever Valinject Gmbh	Composition comprising trabectedin and an amino acid
US20230226051A1 (en)	2022-01-20	2023-07-20	Extrovis Ag	Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5089273A (en)	1986-06-09	1992-02-18	Board Of Trustees Of The University Of Illinois	Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en)	1986-06-09	1993-10-26	The Board Of Trustees Of The University Of Illinois	Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
ATE69234T1 (de) *	1986-06-09	1991-11-15	Univ Illinois	Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) *	1990-11-30	1992-09-22	The Board Of Trustees Of The University Of Illinois	Ecteinascidins 736 and 722
DE3635711A1 (de)	1986-10-21	1988-04-28	Knoll Ag	5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) *	1988-03-04	1988-04-07	Glaxo Group Ltd	Medicaments
GB9101221D0 (en) *	1991-01-19	1991-02-27	Smithkline Beecham Plc	Pharmaceuticals
US5721352A (en)	1991-02-19	1998-02-24	University Of Florida Research Foundation	Entomopoxvirus expression system
FR2697752B1 (fr)	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) *	1992-11-19	1999-04-06	Anticancer, Inc.	Method to produce high levels of methioninase
JPH09503743A (ja) *	1993-05-14	1997-04-15	デポテックコーポレーション	神経学的疾患の治療方法
US5478932A (en) *	1993-12-02	1995-12-26	The Board Of Trustees Of The University Of Illinois	Ecteinascidins
US20040059112A1 (en)	1994-02-18	2004-03-25	Rinehart Kenneth L.	Ecteinascidins
US5919816A (en) *	1994-11-14	1999-07-06	Bionumerik Pharmaceuticals, Inc.	Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en)	1995-04-20	1995-06-07	Univ British Columbia	Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) *	1996-09-18	1998-02-24	President And Fellows Of Harvard College	Process for producing ecteinascidin compounds
EP2298300A1 (en) *	1996-11-05	2011-03-23	The Children's Medical Center Corporation	Compositions for inhibition of anglogenesis comprising thalidomide and aspirin
IL123740A0 (en) *	1997-03-28	1998-10-30	Pfizer	NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en)	1997-04-15	1999-11-16	Univ Illinois	Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) *	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) *	1997-06-05	1998-03-18	Merck & Co Inc	A method of treating cancer
KR100603219B1 (ko)	1998-04-06	2006-07-20	더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈	반합성 엑테이나시딘
KR100643092B1 (ko) *	1998-05-11	2006-11-10	파르마 마르, 에스.에이.	엑테인아시딘 743의 대사산물
US6124292A (en)	1998-09-30	2000-09-26	President And Fellows Of Harvard College	Synthetic analogs of ecteinascidin-743
MY164077A (en)	1999-05-13	2017-11-30	Pharma Mar Sa	Compositions and uses of et743 for treating cancer
AR035842A1 (es)	1999-05-14	2004-07-21	Pharma Mar Sa	Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
WO2001077115A1 (en)	2000-04-12	2001-10-18	Pharma Mar, S.A.	Antitumoral ecteinascidin derivatives
US7247892B2 (en)	2000-04-24	2007-07-24	Taylor Geoff W	Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en)	2000-05-15	2008-09-02	Pharma Mar, S.A.	Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es)	2000-05-15	2003-06-06	Pharma Mar Sa	Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en)	2000-08-11	2003-10-29	City of Hope	The anti-neoplastic agent et-743 inhibits trans activation by sxr
CN100374162C (zh)	2000-11-06	2008-03-12	法马马有限公司	海鞘素－743在制备用于治疗肿瘤的药剂中的应用
EP1360337A1 (en)	2001-02-09	2003-11-12	The Regents Of The University Of California	Ecteinascidin family compounds: compositions and methods
AU2002242561A1 (en)	2001-03-30	2002-10-15	Shire Biochem Inc.	Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
CA2462502A1 (en)	2001-10-19	2003-05-15	Pharma Mar, S.A.	Improved use of antitumoral compound in cancer therapy
US20040019027A1 (en)	2002-04-12	2004-01-29	Barry Forman	Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en)	2003-05-29	2003-07-02	Pharma Mar Sau	Treatment
GB0324201D0 (en)	2003-10-15	2003-11-19	Pharma Mar Sau	Improved antitumoral combinations
PL1689404T3 (pl)	2003-11-13	2009-02-27	Pharma Mar Sau	Połączenie ET-743 z pro lekami 5-fluorouracylu do leczenia raka
GB0326486D0 (en)	2003-11-14	2003-12-17	Pharma Mar Sau	Combination treatment
EP1691809A1 (en)	2003-11-14	2006-08-23	Pharma Mar, S.A.	Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
US20080293725A1 (en)	2004-07-09	2008-11-27	Rafael Rosell Costa	Prognostic Molecular Markers
CA2583464A1 (en)	2004-09-29	2006-04-06	Pharma Mar S.A., Sociedad Unipersonal	Ecteinascidin compounds as anti -inflammatory agents
UA87877C2 (en)	2004-10-26	2009-08-25	Фарма Мар С.А., Сосьедад Униперсональ	Pegylated liposomal doxorubicin in combination with ecteinescidin 743
DK1658848T3 (da)	2004-10-29	2007-11-26	Pharma Mar Sa	Formuleringer omfattende ecteinascidin og et disaccharid
DE602006020335D1 (de)	2005-11-25	2011-04-07	Pharma Mar Sa	Verwendung von parp-1-hemmern
US20100009906A1 (en)	2006-05-12	2010-01-14	Pharma Mar, S.A.	Anticancer Treatments

2000
- 2000-05-13 MY MYPI20002107A patent/MY164077A/en unknown
- 2000-05-15 DE DE60030554T patent/DE60030554T8/de active Active
- 2000-05-15 DK DK06014005.0T patent/DK1716853T3/da active
- 2000-05-15 AU AU45975/00A patent/AU777417B2/en not_active Expired
- 2000-05-15 HU HU0201187A patent/HU229866B1/hu active Protection Beyond IP Right Term
- 2000-05-15 AT AT06011784T patent/ATE375795T1/de active
- 2000-05-15 AT AT06014005T patent/ATE500830T1/de active
- 2000-05-15 CN CN00809976A patent/CN1360503A/zh active Pending
- 2000-05-15 CZ CZ20014081A patent/CZ301482B6/cs not_active IP Right Cessation
- 2000-05-15 KR KR1020017014479A patent/KR20020019914A/ko active Search and Examination
- 2000-05-15 PT PT00927584T patent/PT1176964E/pt unknown
- 2000-05-15 JP JP2000617900A patent/JP2002544231A/ja not_active Withdrawn
- 2000-05-15 DK DK00927584T patent/DK1176964T3/da active
- 2000-05-15 DE DE122008000013C patent/DE122008000013I1/de active Pending
- 2000-05-15 NZ NZ515423A patent/NZ515423A/en not_active IP Right Cessation
- 2000-05-15 TR TR2001/03819T patent/TR200103819T2/xx unknown
- 2000-05-15 SI SI200031067T patent/SI1716853T1/sl unknown
- 2000-05-15 DE DE60036826T patent/DE60036826T2/de not_active Expired - Lifetime
- 2000-05-15 SI SI200030905T patent/SI1176964T1/sl unknown
- 2000-05-15 IL IL14643400A patent/IL146434A0/xx active IP Right Grant
- 2000-05-15 EP EP06011784A patent/EP1702618B1/en not_active Expired - Lifetime
- 2000-05-15 CA CA002373794A patent/CA2373794C/en not_active Expired - Lifetime
- 2000-05-15 UA UA2001128559A patent/UA74782C2/uk unknown
- 2000-05-15 ES ES06011784T patent/ES2294756T3/es not_active Expired - Lifetime
- 2000-05-15 PL PL352931A patent/PL198185B1/pl unknown
- 2000-05-15 ES ES00927584T patent/ES2272279T3/es not_active Expired - Lifetime
- 2000-05-15 PT PT06014005T patent/PT1716853E/pt unknown
- 2000-05-15 BR BR0010531-7A patent/BR0010531A/pt not_active Application Discontinuation
- 2000-05-15 EP EP00927584A patent/EP1176964B8/en not_active Expired - Lifetime
- 2000-05-15 EP EP06014005A patent/EP1716853B9/en not_active Expired - Lifetime
- 2000-05-15 WO PCT/GB2000/001857 patent/WO2000069441A1/en active IP Right Grant
- 2000-05-15 MX MXPA01011562A patent/MXPA01011562A/es active IP Right Grant
- 2000-05-15 SI SI200030977T patent/SI1702618T1/sl unknown
- 2000-05-15 AR ARP000102321A patent/AR028476A1/es not_active Application Discontinuation
- 2000-05-15 AT AT00927584T patent/ATE338552T1/de active
- 2000-05-15 SK SK1644-2001A patent/SK287580B6/sk not_active IP Right Cessation
- 2000-05-15 DK DK06011784T patent/DK1702618T3/da active
- 2000-05-15 CN CNB2005100091622A patent/CN100477993C/zh not_active Expired - Lifetime
- 2000-05-15 PT PT06011784T patent/PT1702618E/pt unknown
- 2000-05-15 DE DE60045720T patent/DE60045720D1/de not_active Expired - Lifetime
2001
- 2001-11-11 IL IL146434A patent/IL146434A/en active Protection Beyond IP Right Term
- 2001-11-12 NO NO20015516A patent/NO324564B1/no not_active IP Right Cessation
- 2001-12-03 BG BG106171A patent/BG65680B1/bg unknown
2005
- 2005-01-14 AU AU2005200180A patent/AU2005200180B9/en not_active Expired
2006
- 2006-11-30 CY CY20061101734T patent/CY1105818T1/el unknown
2007
- 2007-06-28 US US11/769,873 patent/US8119638B2/en not_active Expired - Fee Related
2008
- 2008-01-16 CY CY20081100059T patent/CY1107143T1/el unknown
- 2008-02-22 NL NL300337C patent/NL300337I2/nl unknown
- 2008-03-10 LU LU91418C patent/LU91418I2/fr unknown
- 2008-04-07 CY CY200800007C patent/CY2008007I2/el unknown
- 2008-04-16 FR FR08C0013C patent/FR08C0013I2/fr active Active
- 2008-05-16 NO NO2008005C patent/NO2008005I1/no not_active IP Right Cessation
2011
- 2011-06-08 CY CY20111100545T patent/CY1112753T1/el unknown
2012
- 2012-05-02 JP JP2012105249A patent/JP5777562B2/ja not_active Expired - Lifetime
2015
- 2015-01-06 HU HUS1500001C patent/HUS1500001I1/hu unknown

Also Published As

Publication number	Publication date
DE60030554D1 (de)	2006-10-19
AU777417B2 (en)	2004-10-14
HUS1500001I1 (hu)	2016-08-29
CY2008007I1 (el)	2009-11-04
BG65680B1 (bg)	2009-06-30
CY1112753T1 (el)	2016-02-10
HUP0201187A3 (en)	2002-11-28
EP1716853A2 (en)	2006-11-02
EP1716853B9 (en)	2011-09-28
JP5777562B2 (ja)	2015-09-09
ATE500830T1 (de)	2011-03-15
EP1716853A3 (en)	2006-11-15
NO324564B1 (no)	2007-11-19
CN1679631A (zh)	2005-10-12
WO2000069441A1 (en)	2000-11-23
CY2008007I2 (el)	2009-11-04
NO20015516D0 (no)	2001-11-12
NL300337I1 (nl)	2008-05-01
EP1716853B1 (en)	2011-03-09
DK1176964T3 (da)	2007-01-15
NO20015516L (no)	2002-01-11
DK1702618T3 (da)	2008-02-25
NO2008005I2 (sl)	2010-09-27
EP1176964A1 (en)	2002-02-06
ES2272279T3 (es)	2007-05-01
CY1105818T1 (el)	2011-02-02
US8119638B2 (en)	2012-02-21
DE60030554T2 (de)	2007-09-13
EP1176964B8 (en)	2007-10-10
UA74782C2 (uk)	2006-02-15
PT1716853E (pt)	2011-05-12
CA2373794A1 (en)	2000-11-23
JP2002544231A (ja)	2002-12-24
EP1702618A2 (en)	2006-09-20
CZ20014081A3 (cs)	2002-11-13
LU91418I9 (sl)	2019-01-02
LU91418I2 (fr)	2008-05-13
CA2373794C (en)	2005-10-11
SK16442001A3 (sk)	2002-03-05
SK287580B6 (sk)	2011-03-04
NO2008005I1 (no)	2008-06-09
NZ515423A (en)	2004-04-30
PL198185B1 (pl)	2008-06-30
CN1360503A (zh)	2002-07-24
BG106171A (en)	2002-06-28
CY1107143T1 (el)	2010-07-28
PL352931A1 (en)	2003-09-22
AU2005200180A1 (en)	2005-02-10
ATE338552T1 (de)	2006-09-15
AR028476A1 (es)	2003-05-14
TR200103819T2 (tr)	2002-04-22
MXPA01011562A (es)	2002-07-30
DE60030554T8 (de)	2008-01-10
DE60036826D1 (de)	2007-11-29
HU229866B1 (en)	2014-10-28
EP1702618A3 (en)	2006-12-27
DE122008000013I1 (de)	2008-08-07
IL146434A0 (en)	2002-07-25
US20070275942A1 (en)	2007-11-29
CZ301482B6 (cs)	2010-03-17
JP2012149095A (ja)	2012-08-09
DK1716853T3 (da)	2011-06-27
SI1702618T1 (sl)	2008-02-29
NL300337I2 (nl)	2008-09-01
SI1716853T1 (sl)	2011-10-28
EP1702618B1 (en)	2007-10-17
KR20020019914A (ko)	2002-03-13
PT1702618E (pt)	2008-01-11
CN100477993C (zh)	2009-04-15
EP1176964B1 (en)	2006-09-06
FR08C0013I1 (sl)	2008-05-30
AU2005200180B9 (en)	2008-05-29
FR08C0013I2 (fr)	2009-10-30
PT1176964E (pt)	2007-01-31
AU4597500A (en)	2000-12-05
ATE375795T1 (de)	2007-11-15
BR0010531A (pt)	2002-06-04
HUP0201187A2 (en)	2002-09-28
AU2005200180B2 (en)	2007-12-13
DE60045720D1 (de)	2011-04-21
DE60036826T2 (de)	2008-08-28
MY164077A (en)	2017-11-30
IL146434A (en)	2008-03-20
ES2294756T3 (es)	2008-04-01

Publication	Publication Date	Title
SI1176964T1 (sl)	2007-02-28	Uporaba et743 za zdravljenje raka
EP1320376A4 (en)	2005-06-15	TREATMENT OF PROSTATE CANCER
IL148579A0 (en)	2002-09-12	Oncolytic combinations for the treatment of cancer
AU8322401A (en)	2002-02-18	Indole compounds useful for the treatment of cancer
IL124650A0 (en)	1998-12-06	Methods and therapeutic compositions for treating cancer
EP1282411A4 (en)	2008-05-21	ANTICANCER TREATMENT METHOD
AU7636800A (en)	2001-05-10	Improved ricin-like toxins for treatment of cancer
IL149281A0 (en)	2002-11-10	Treatment of cancer
AU5552400A (en)	2001-01-09	Treatment of cancer
GB9819999D0 (en)	1998-11-04	Treatment of cancer
GB0026015D0 (en)	2000-12-13	Cancer treatment
HRP20020262A2 (en)	2004-04-30	Substituted pyrroles as antiproliferative agents for the treatment of cancer
PL353769A1 (en)	2003-12-01	Chemically-stabilized chlorite solutions for treating cancer
GB9804361D0 (en)	1998-04-22	Cancer treatment
AU1036801A (en)	2001-04-30	Agent for treating cephalic pain
AU4598100A (en)	2000-12-05	Treating cancer
GB9903035D0 (en)	1999-03-31	Treating cancer
GB9911183D0 (en)	1999-07-14	Treatment of cancers
GB2334579B (en)	2003-06-04	Treating cancer
GB9914971D0 (en)	1999-08-25	Treating cancer
GB0007254D0 (en)	2000-05-17	Treating cancer
GB9908176D0 (en)	1999-06-02	Cancer treatment
GB9927106D0 (en)	2000-01-12	Cancer treatment
GB9911346D0 (en)	1999-07-14	Treatment of cancers
GB9918534D0 (en)	1999-10-06	Treatment of cancers